TUCSON, Ariz., March 31 /PRNewswire/ -- ImaRx Therapeutics, Inc., a
biopharmaceutical company developing and commercializing therapies for
vascular disorders, today provided a corporate update along with fourth
quarter and full year 2007 financial results.
2007 Year in Review:
-- Initiated TUCSON Phase I/II clinical study
-- Received FDA approval to market urokinase under new trade name
-- Signed strategic licensing agreement with Bracco International
-- Completed Initial Public Offering
-- Awarded Phase I STTR grant from the National Institutes of Health
-- Signed research collaboration with Royal Philips Electronics
-- Extended expiration dating of urokinase product inventory
Key Corporate Highlights:
PhaseI/II TUCSON Clinical Trial and SonoLysis Program Update
In January of 2007, the Company initiated its TUCSON trial, a Phase I/II clinical study designed to assess the safety of the Company's proprietary MRX- 801 microbubbles in combination with ultrasound and tPA in ischemic stroke patients. The TUCSON trial was designed with four 18-patient cohorts to evaluate increasing doses of MRX-801. In the second dose cohort, the Company observed a greater number of reported symptomatic intracranial hemorrhages in subjects receiving treatment relative to controls and after consultation with the Data and Safety Monitoring Board elected to stop enrollment of the study.
Bradford A. Zakes, President and CEO stated, "Although we would have
preferred to obtain more efficacy and safety data at higher doses of
microbubbles, we were encouraged by the data from the first cohort of
patients. One vial of MRX-801 in combination with ultrasound and tPA did
not result in any reported cases of intracranial hemorrhage in the
treatment group, suggesting a safe dose for further clinical studies.
Furthermore, an analysis of activity from the first cohort indicated a
|SOURCE ImaRx Therapeutics, Inc.|
Copyright©2008 PR Newswire.
All rights reserved